Genfit SA
PAR:GNFT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.965
5.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Genfit SA
Additional Paid In Capital
Genfit SA
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genfit SA
PAR:GNFT
|
Additional Paid In Capital
€446.5m
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
17%
|
|
|
Valneva SE
PAR:VLA
|
Additional Paid In Capital
€593.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nanobiotix SA
PAR:NANO
|
Additional Paid In Capital
€312.7m
|
CAGR 3-Years
7%
|
CAGR 5-Years
16%
|
CAGR 10-Years
22%
|
|
|
Inventiva SA
PAR:IVA
|
Additional Paid In Capital
€201.9m
|
CAGR 3-Years
13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Additional Paid In Capital
€33.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-12%
|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Additional Paid In Capital
€76.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
Genfit SA
Glance View
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
See Also
What is Genfit SA's Additional Paid In Capital?
Additional Paid In Capital
446.5m
EUR
Based on the financial report for Jun 30, 2024, Genfit SA's Additional Paid In Capital amounts to 446.5m EUR.
What is Genfit SA's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
17%
Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for Genfit SA have been 2% over the past three years , 3% over the past five years , and 17% over the past ten years .
You don't have any saved screeners yet
